Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

Original title: “Novartis to pay $125M for blood-brain barrier crossing platform”

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

Original title: “Novo looks to Anthropic’s AI models to ‘supercharge’ drug development”

A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

Original title: “Sling banks $123M for an experimental thyroid eye disease pill”

The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

Original title: “Skyhawk racks up more support for Huntington’s drug”

As AI becomes more embedded in biotech R&D, companies are competing for professionals who can bridge biology, machine learning, data and engineering. Recruiting expert Darren Nelson explains which capabilities are becoming hardest to find—and why.

Original title: “AI is changing the talent biotech companies compete to hire”

A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.

Original title: “5 biotechs braving the commercial waters with product launches”

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing.

Original title: “FDA launches pilot program to speed up early US drug research”

After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.

Original title: “GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M”

Orvida’s management team comprises ... disease therapeutics. ... Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. The group is uniquely structured to provide treatments across Specialty & Primary Care, Consumer Healthcare and Rare Diseases. Its fully integrated operations span clinical development, ... Orvida’s management team comprises industry leaders with deep expertise in drug discovery, dermatological pharmaceutical development, and rare disease therapeutics. ... Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. The group is uniquely structured to provide treatments across Specialty & Primary Care, Consumer Healthcare and Rare Diseases. Its fully integrated operations span clinical development, manufacturing of active ingredients and finished products, commercialization and licensing. Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 With favorable Phase 1a safety data supporting the program and ontivatrep now being evaluated in patients for the first time, we are focused on delivering the clinical data needed to guide its continued development. We look forward to building on this momentum and working toward advancing a potential new treatment option for patients living with Olmsted syndrome.” · Ontivatrep is being developed for Olmsted syndrome, severe keratodermas and ichthyosis, rare genetic skin diseases characterized by significant unmet medical need. 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma, a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases, today announced the completion of an interim financing led by Recordati, a global pharmaceutical group headquartered in Milan, Italy, with a dedicated Rare Diseases business, alongside continued participation from Orvida’s existing shareholders.

Original title: “Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases”

Blood centers have the donors, resources and community footprint drug sponsors need to solve supply chain issues around cell and gene therapies.

Original title: “Blood centers can help biopharma scale cell and gene therapies”

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to MedGene Therapeutics, Inc. ("MedGene"), a company located in Silver Spring, Maryland, the United States of America.

Original title: “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers”

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

Original title: “Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results”